Binglan Zhang1, Fuping Zhu2, Xuelei Ma1, Ye Tian3, Dan Cao1, Songe Luo1, Yu Xuan1, Lei Liu4, Yuquan Wei1. 1. Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, People's Republic of China. 2. The Department of Hepatobiliary Surgery, The Ninth People's Hospital of Chongqing, People's Republic of China. 3. The Department of Sonography, West China Hospital, Sichuan University, Chengdu, People's Republic of China. 4. Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, People's Republic of China. Electronic address: liuleihx@gmail.com.
Abstract
PURPOSE: A population-based matched-pair comparison was performed to compare the efficacy of stereotactic body radiotherapy (SBRT) versus surgery for early-stage non-small cell lung cancer (NSCLC). METHODS: All the eligible studies were searched by PubMed, Medline, Embase, and the Cochrane Library. The meta-analysis was performed to compare odds ratios (OR) for overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), local control (LC), and distant control (DC). RESULTS: Six studies containing 864 matched patients were included in the meta-analysis. The surgery was associated with a better long-term OS in patients with early-stage NSCLC. The pooled OR and 95% confidence interval (CI) for 1-year, 3-year OS were 1.31 [0.90, 1.91] and 1.82 [1.38, 2.40], respectively. However, the difference in 1-year and 3-year CSS, DFS, LC and DC was not significant. CONCLUSIONS: This systematic review found a superior 3-year OS after surgery compared with SBRT, which supports the need to compare both treatments in large prospective, randomized, controlled clinical trials.
PURPOSE: A population-based matched-pair comparison was performed to compare the efficacy of stereotactic body radiotherapy (SBRT) versus surgery for early-stage non-small cell lung cancer (NSCLC). METHODS: All the eligible studies were searched by PubMed, Medline, Embase, and the Cochrane Library. The meta-analysis was performed to compare odds ratios (OR) for overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), local control (LC), and distant control (DC). RESULTS: Six studies containing 864 matched patients were included in the meta-analysis. The surgery was associated with a better long-term OS in patients with early-stage NSCLC. The pooled OR and 95% confidence interval (CI) for 1-year, 3-year OS were 1.31 [0.90, 1.91] and 1.82 [1.38, 2.40], respectively. However, the difference in 1-year and 3-year CSS, DFS, LC and DC was not significant. CONCLUSIONS: This systematic review found a superior 3-year OS after surgery compared with SBRT, which supports the need to compare both treatments in large prospective, randomized, controlled clinical trials.
Authors: Varun Puri; Traves D Crabtree; Jennifer M Bell; Stephen R Broderick; Daniel Morgensztern; Graham A Colditz; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Bryan F Meyers; Aalok Patel; Clifford G Robinson Journal: J Thorac Oncol Date: 2015-12 Impact factor: 15.609
Authors: Rhami Khorfan; Timothy J Kruser; Julia M Coughlin; Ankit Bharat; Karl Y Bilimoria; David D Odell Journal: Ann Thorac Surg Date: 2020-03-05 Impact factor: 4.330
Authors: Percy Lee; Billy W Loo; Tithi Biswas; George X Ding; Issam M El Naqa; Andrew Jackson; Feng-Ming Kong; Tamara LaCouture; Moyed Miften; Timothy Solberg; Wolfgang A Tome; An Tai; Ellen Yorke; X Allen Li Journal: Int J Radiat Oncol Biol Phys Date: 2019-04-05 Impact factor: 8.013